CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
lisdexamfetamine dimesylate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01342445
NCT01342445Phase 4Completed

Effects of Vyvanse on the Behavioral, Academic, and Psychosocial Functioning of College Students With ADHD

University of Rhode Island·interventional·Posted Apr 27, 2011·Updated Apr 24, 2025

In Brief

A Phase 4 clinical trial evaluating lisdexamfetamine dimesylate and Placebo for Attention-deficit/Hyperactivity Disorder. Completed, enrolled 50 participants across 2 sites.

Detailed Summary

The purpose of this study was to evaluate the effects of lisdexamfetamine dimesylate, a prodrug stimulant, on the behavioral, academic, and psychosocial functioning of college students with attention-deficit/hyperactivity disorder (ADHD). Twenty-five college students with ADHD from two universities (University of Rhode Island and Lehigh University) completed a within-subject, placebo-controlled research trial. Dependent measures tapping behavioral, psychosocial, and academic functioning were completed on a weekly basis across five conditions (baseline, placebo, and 30-mg, 50-mg, and 70-mg lisdexamfetamine).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsLehigh University

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 27, 2011
Enrollment StartSep 1, 2009
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.2 years ago

Interventions

lisdexamfetamine dimesylatedrug

30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design

Placebodrug